Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome. Haqq AM, Poitou C, Chung WK, Forsythe E, et al. J Clin Endocrinol Metab 2025;110:e3271-e3282.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Haqq AM, Poitou C, Chung WK, Forsythe E, et al. Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome. J Clin Endocrinol Metab 2025;110:e3271-e3282.
PMID: 39919037